Gracell Biotechnology Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Suzhou China (2017)
Status: Acquired by AstraZeneca (2023)

Organization Overview

First Clinical Trial
2018
NCT03559439
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gracell Biopharmaceuticals, Inc. | Gracell Biotechnologies (Shanghai) Co., Ltd | Gracell Biotechnology Ltd. | Gracell Biotechnology Shanghai Co., Ltd.